TITLE

Natalizumab and PML: a risky business?

AUTHOR(S)
Clifford, David B.
PUB. DATE
October 2008
SOURCE
Gut;Oct2008, Vol. 57 Issue 10, p1347
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the development of treatments including natalizumab (Tysabri), a drug used to treat Crohn's disease. It cites that the drug is a humanized monoclonal antibody against 4-integrin, which is first approved for treatment on relapsing multiple sclerosis (MS). It contends that this drug minimizes the activity of MS as shown by the development of magnetic resonance (MR) brain lesions and slowing progression of disability.
ACCESSION #
34640810

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics